Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 82

Results For "Eni"

2278 News Found

Granules India received ANDA approval for Sildenafil for oral suspension
Drug Approval | December 06, 2023

Granules India received ANDA approval for Sildenafil for oral suspension

The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million


Zydus receives final approval from the USFDA for Ivabradine Tablets
Drug Approval | December 06, 2023

Zydus receives final approval from the USFDA for Ivabradine Tablets

Ivabradine Tablets, 5 mg and 7.5 mg had annual sales of USD 136.5 mn in the United States


AIIA initiates training programme on latent tuberculosis infections
Healthcare | December 02, 2023

AIIA initiates training programme on latent tuberculosis infections

The workshop is specially curated for Ayurvedic medical officers from Delhi and Haryana


Biocon Biologics completes Integration of Viatris' Biosimilar business
News | December 01, 2023

Biocon Biologics completes Integration of Viatris' Biosimilar business

The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone


Roche expands hepatitis diagnostics portfolio
Diagnostic Center | November 29, 2023

Roche expands hepatitis diagnostics portfolio

Almost 300 million people globally have chronic hepatitis B


BrainSpec receives FDA clearance to begin using AI-backed solution for non-invasive brain chemistry measurement
Digitisation | November 28, 2023

BrainSpec receives FDA clearance to begin using AI-backed solution for non-invasive brain chemistry measurement

First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease


Fortis Healthcare to divest Fortis Malar Hospital, Chennai to MGM Healthcare
News | November 28, 2023

Fortis Healthcare to divest Fortis Malar Hospital, Chennai to MGM Healthcare

The divestment is a part of Fortis' ongoing portfolio rationalization strategy


GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep
News | November 28, 2023

GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep

Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex


DxVx plans to make a license-in agreement of OVM-200
News | November 25, 2023

DxVx plans to make a license-in agreement of OVM-200

Final stage in licensing OVM-200 from Oxford Vacmedix in the UK